Physician profile
Julian Espiritu
NPI 1730174970
$214,957.84
in general payments reported to CMS, 2019-2025
38 companies · $31K in 2025
The $31K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $14K · 2021: $19K · 2022: $18K · 2023: $25K · 2024: $32K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Food and Beverage: $16K · Travel and Lodging: $11K · Honoraria: $8,975 · Consulting Fee: $6,259 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,310.00 |
| Food and Beverage | $16,488.34 |
| Travel and Lodging | $10,561.07 |
| Honoraria | $8,975.00 |
| Consulting Fee | $6,258.81 |
| Education | $200.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46,316.34 | 2019-2020 | |
| Horizon Therapeutics Plc | $34,427.84 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,615.33 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $30,029.04 | 2019 | |
| Amgen INC. | $15,469.75 | 2019-2025 | Krystexxa, Evenity, Prolia |
| Lilly USA, LLC | $12,996.94 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $10,974.92 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Sobi, INC | $6,825.40 | 2023 | |
| Aurinia Pharma U.S., INC. | $6,135.29 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $4,630.38 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $4,265.48 | 2022-2025 | |
| Vifor Pharma, INC. | $2,492.39 | 2019-2025 | Veltassa, Korsuva |
| Novo Nordisk INC | $1,807.79 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Mallinckrodt Hospital Products INC. | $1,493.46 | 2021-2024 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $1,173.13 | 2022-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $790.71 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $705.10 | 2022-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $685.12 | 2024-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $674.91 | 2020-2025 | Benlysta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $437.54 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $437.18 | 2020-2025 | |
| Daiichi Sankyo INC. | $323.91 | 2019-2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $320.42 | 2023-2024 | Inpefa |
| Ardelyx, INC. | $188.06 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Sanofi-Aventis U.S. LLC | $143.47 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $125.34 | 2021-2024 | Rayaldee |
| Scpharmaceuticals INC. | $104.44 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $86.45 | 2019 | |
| Shield Therapeutics INC | $54.53 | 2022-2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $50.53 | 2019-2021 | |
| Akebia Therapeutics INC | $36.68 | 2022 | |
| Xeris Pharmaceuticals, INC. | $32.48 | 2022-2025 | Keveyis |
| Takeda Pharmaceuticals U.S.A., INC. | $20.29 | 2023 | Gattex |
| Ultragenyx Pharmaceutical INC. | $19.20 | 2023 | |
| Chiesi USA, INC. | $19.09 | 2021 | |
| Abbott Laboratories | $17.54 | 2023 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $15.75 | 2024 | Crysvita |
| Baxter Healthcare | $15.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Espiritu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.